UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A Randomized Phase II Study of LY2510924 and Carboplatin/Etoposide versus Carboplatin/Etoposide in Extensive‐Disease Small Cell Lung Cancer

Lung cancer (Amsterdam, Netherlands), 2017-03, Vol.105, p.7-13

2017

Volltextzugriff (PDF)

A decade of innovation in pharmaceutical R&D: the Chorus model

Nature reviews. Drug discovery, 2015-01, Vol.14 (1), p.17-28

2015

Volltextzugriff (PDF)

Discovery of 6‑(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl‑1H‑indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia

Journal of medicinal chemistry, 2015-12, Vol.58 (24), p.9768-9772

2015

Volltextzugriff (PDF)

Distinct mobilization of leukocytes and hematopoietic stem cells by CXCR4 peptide antagonist LY2510924 and monoclonal antibody LY2624587

Oncotarget, 2017-11, Vol.8 (55), p.94619-94634

2017

Volltextzugriff (PDF)

A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer

Clinical cancer research, 2014-07, Vol.20 (13), p.3581-3588

2014

Volltextzugriff (PDF)

A randomized clinical efficacy study targeting mPGES1 or EP4 in dogs with spontaneous osteoarthritis

Science translational medicine, 2019-10, Vol.11 (516)

2019

Volltextzugriff (PDF)

Aurora kinase A inhibitor, LY3295668 erbumine: a phase 1 monotherapy safety study in patients with locally advanced or metastatic solid tumors

Investigational new drugs, 2021-08, Vol.39 (4), p.1001-1010

2021

Volltextzugriff (PDF)

Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study

Investigational new drugs, 2017-06, Vol.35 (3), p.334-344

2017

Volltextzugriff (PDF)

A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC)

Targeted oncology, 2016-10, Vol.11 (5), p.643-653

2016

Volltextzugriff (PDF)

Construction of Hydroxylated Alkaloids (.+-.)-Mannonolactam, (.+-.)-Deoxymannojirimycin, and (.+-.)-Prosopinine through Aza-Annulation

Journal of organic chemistry, 1994-07, Vol.59 (13), p.3575-3584

1994

Volltextzugriff (PDF)

Heterocycle Formation through Aza-Annulation: Stereochemically Controlled Syntheses of (.+-.)-5-Epitashiromine and (.+-.)-Tashiromine

Journal of organic chemistry, 1994-04, Vol.59 (7), p.1613-1620

1994

Volltextzugriff (PDF)

Formation of Dihydropyridone- and Pyridone-Based Peptide Analogs through Aza-Annulation of β-Enamino Ester and Amide Substrates with α-Amido Acrylate Derivatives

Journal of organic chemistry, 1997-02, Vol.62 (4), p.1033-1042

1997

Volltextzugriff (PDF)

Asymmetric Formation of Quaternary Centers through Aza-Annulation of Chiral β-Enamino Amides with Acrylate Derivatives

Journal of the American Chemical Society, 1998-03, Vol.120 (11), p.2493-2500

1998

Volltextzugriff (PDF)

Stereoselective formation of dimethylcyclopentanes through intramolecular Ziegler-Natta alkene insertion

Organometallics, 1990-12, Vol.9 (12), p.3022-3025

1990

Volltextzugriff (PDF)

A phase Ib study of oral Chk1 inhibitor LY2880070 as monotherapy in patients with advanced or metastatic cancer

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.3579-3579

2020

Volltextzugriff (PDF)

Preparation of 3-aza-Cope rearrangement of N-alkyl-N-allyl enamines

Journal of organic chemistry, 1991-09, Vol.56 (19), p.5578-5583

1991

Volltextzugriff (PDF)

Abstract CT083: A Phase I/II study of aurora kinase A inhibitor, LY3295668 erbumine (AK-01): Safety as monotherapy in patients with locally advanced or metastatic solid tumors

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.CT083-CT083

2019

Volltextzugriff (PDF)

Abstract CT019: Population pharmacokinetics of an aurora kinase A inhibitor, LY3295668 erbumine (AK-01), in patients with locally advanced or metastatic solid tumors

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.CT019-CT019

2019

Volltextzugriff (PDF)

A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine in patients with advanced or metastatic cancer

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.3581-3581

2020

Volltextzugriff (PDF)

Aza-annulation as a versatile approach to the synthesis of non-benzodiazepene compounds for the treatment of sleep disorders

Tetrahedron letters, 1997-12, Vol.38 (49), p.8475-8478

1997

Volltextzugriff (PDF)

Transition-metal-catalyzed asymmetric organic synthesis via polymer-attached optically active phosphine ligands. 5. Preparation of amino acids in high optical yield via catalytic hydrogenation

Journal of organic chemistry, 1981-07, Vol.46 (14), p.2954-2960

1981

Volltextzugriff (PDF)

Asymmetric Formation of Quaternary Centers through Aza-Annulation of Chiral .beta.-Enamino Esters with Acrylate Derivatives

Journal of the American Chemical Society, 1994-07, Vol.116 (14), p.6201-6206

1994

Volltextzugriff (PDF)

Formation of 1,2,3,4-tetrahydro-2-pyridones by aza-annulation of imines with acrylate derivatives

Journal of organic chemistry, 1992-09, Vol.57 (20), p.5319-5328

1992

Volltextzugriff (PDF)

Evaluation of CXCR4 expression on tumor and circulating tumor cells (CTCs) as predictive response marker for CXCR4 antagonist LY2510924 in combination with carboplatin-etoposide in extensive-disease small cell lung cancer (ED-SCLC)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.7567-7567

2015

Volltextzugriff (PDF)

1 – 25 von 77

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(60)
Mit Volltextzugriff
(73)

Publikationsform

Sprache

Englisch
(77)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A Randomized Phase II Study of LY2510924 and Carboplatin/Etoposide versus Carboplatin/Etoposide in Extensive‐Disease Small Cell Lung Cancer

A decade of innovation in pharmaceutical R&D: the Chorus model

Discovery of 6‑(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl‑1H‑indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia

Distinct mobilization of leukocytes and hematopoietic stem cells by CXCR4 peptide antagonist LY2510924 and monoclonal antibody LY2624587

The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer

A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer

A randomized clinical efficacy study targeting mPGES1 or EP4 in dogs with spontaneous osteoarthritis

Aurora kinase A inhibitor, LY3295668 erbumine: a phase 1 monotherapy safety study in patients with locally advanced or metastatic solid tumors

Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study

A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC)

Construction of Hydroxylated Alkaloids (.+-.)-Mannonolactam, (.+-.)-Deoxymannojirimycin, and (.+-.)-Prosopinine through Aza-Annulation

Heterocycle Formation through Aza-Annulation: Stereochemically Controlled Syntheses of (.+-.)-5-Epitashiromine and (.+-.)-Tashiromine

Formation of Dihydropyridone- and Pyridone-Based Peptide Analogs through Aza-Annulation of β-Enamino Ester and Amide Substrates with α-Amido Acrylate Derivatives

Asymmetric Formation of Quaternary Centers through Aza-Annulation of Chiral β-Enamino Amides with Acrylate Derivatives

Stereoselective formation of dimethylcyclopentanes through intramolecular Ziegler-Natta alkene insertion

A phase Ib study of oral Chk1 inhibitor LY2880070 as monotherapy in patients with advanced or metastatic cancer

Preparation of 3-aza-Cope rearrangement of N-alkyl-N-allyl enamines

Abstract CT083: A Phase I/II study of aurora kinase A inhibitor, LY3295668 erbumine (AK-01): Safety as monotherapy in patients with locally advanced or metastatic solid tumors

Abstract CT019: Population pharmacokinetics of an aurora kinase A inhibitor, LY3295668 erbumine (AK-01), in patients with locally advanced or metastatic solid tumors

A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine in patients with advanced or metastatic cancer

Aza-annulation as a versatile approach to the synthesis of non-benzodiazepene compounds for the treatment of sleep disorders

Transition-metal-catalyzed asymmetric organic synthesis via polymer-attached optically active phosphine ligands. 5. Preparation of amino acids in high optical yield via catalytic hydrogenation

Asymmetric Formation of Quaternary Centers through Aza-Annulation of Chiral .beta.-Enamino Esters with Acrylate Derivatives

Formation of 1,2,3,4-tetrahydro-2-pyridones by aza-annulation of imines with acrylate derivatives

Evaluation of CXCR4 expression on tumor and circulating tumor cells (CTCs) as predictive response marker for CXCR4 antagonist LY2510924 in combination with carboplatin-etoposide in extensive-disease small cell lung cancer (ED-SCLC)

Suchergebnisse filtern